STOCK TITAN

Replimune Group SEC Filings

REPL NASDAQ

Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Sorting through hundreds of pages that detail viral engineering, Phase data, and milestone payments is challenging for any biotech investor. Replimune Group Inc’s filings layer complex clinical trial disclosures onto traditional financial statements, making it tough to pinpoint cash-runway metrics or track when insiders buy shares. Stock Titan’s AI-powered analysis breaks down every section, so understanding Replimune Group Inc SEC documents with AI becomes a five-minute task instead of a full afternoon.

Need the latest Replimune Group Inc quarterly earnings report 10-Q filing? Our real-time feed grabs it from EDGAR seconds after it posts and delivers an executive summary highlighting R&D spend and trial timelines. Wondering about Replimune Group Inc insider trading Form 4 transactions? We tag each filing and send instant alerts on Replimune Group Inc Form 4 insider transactions real-time, helping you gauge management’s confidence. You can also dive into the Replimune Group Inc annual report 10-K simplified to see cash burn projections, or review the Replimune Group Inc proxy statement executive compensation to compare stock-based awards across leadership.

Our platform covers every form—10-K, 10-Q, 8-K, S-3, SC 13G—plus a dedicated stream for Replimune Group Inc 8-K material events explained. Built-in AI models surface key numbers, flag changes in trial enrollment, and translate biotech jargon into plain language. The result: Replimune Group Inc SEC filings explained simply. Use it to perform Replimune Group Inc earnings report filing analysis, monitor Replimune Group Inc executive stock transactions Form 4, and stay ahead of material catalysts—without wading through dense regulatory prose.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Replimune Group (REPL)?

The current stock price of Replimune Group (REPL) is $9.33 as of June 28, 2025.

What is the market cap of Replimune Group (REPL)?

The market cap of Replimune Group (REPL) is approximately 711.5M.

What is the primary focus of Replimune Group Inc?

Replimune Group Inc is focused on developing oncolytic immunotherapies to treat solid tumors, using its proprietary RPx platform to activate both local and systemic immune responses.

What is the RPx platform?

The RPx platform is a proprietary technology that uses a genetically engineered herpes simplex virus 1 backbone to deliver immunostimulatory payloads, enhancing tumor cell killing and immune activation.

Which product candidates are central to their pipeline?

The company's core pipeline includes RP1, RP2, and RP3, each designed with unique mechanisms to target cancer cells and stimulate the immune system through various immunomodulatory strategies.

How does Replimune generate revenue as a clinical-stage company?

At this stage, Replimune primarily relies on strategic investments, partnerships, and research collaborations, as it advances its clinical candidates toward potential commercialization.

What differentiates Replimune's approach to cancer treatment?

The company’s dual mechanism of direct virus-mediated tumor lysis and systemic immune activation sets it apart, potentially providing synergistic benefits when combined with other cancer therapies.

What is the significance of oncolytic immunotherapies?

Oncolytic immunotherapies use viruses to selectively target and destroy cancer cells while stimulating the body's immune system, which may help overcome resistance seen with conventional treatments.

Where is Replimune Group Inc headquartered?

Replimune Group Inc is headquartered in Woburn, Massachusetts and was established in 2015, positioning it as a long-established player in the biotech sector.
Replimune Group

NASDAQ:REPL

REPL Rankings

REPL Stock Data

711.51M
72.57M
4.18%
101.93%
11.87%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WOBURN